Introduction
The syndrome of inappropriate lactation has been shown usually to be associated with increased circulating prolactin levels (Frantz and Kleinberg, 1970; Forsyth et al., 1971; Hwang et al., 1971) . Bromocriptine (2-brom-a-ergocryptine, CB 154) specifically reduces prolactin secretion by an action at the pituitary level and has been shown to be effective in the suppression of lactation whether it be puerperal (Varga et al., 1972; Rolland and Shellekens, 1973) or pathological, and this is associated with a reduction in circulating prolactin levels (Lutterbeck et al., 1971; Leutenegger et al., 1972; Varga et al., 1973) . Inappropriate lactation with high prolactin levels is usually associated with hypogonadism whether this be menstrual irregularity or amenorrhoea in women or impotence in men; early reports indicated that the gonadal function returns to normal as the hyperprolactinaemia and galactorrhoea abate during the early phases of bromocriptine therapy (Lutterbeck et al., 1971;  Leutenegger et al., 1972; Varga et al., 1973) .
We report our experience with long-term treatment of the galactorrhoea-hypogonadism syndrome with bromocriptine in 17 women and four men.
Patients
The 21 patients (tables I and II) were first seen at St. Bartholomew's Hospital between 1969 and . Preliminary accounts of five of them have been given elsewhere (cases 1, 4, 10, 18, and 19; . No patient had evidence of hepatic or G. M. BESSER renal disease and none gave a history of taking a drug likely to cause galactorrhoea, except for oestrogen and progestogen therapy in four cases. Six of the patients had previously been pregnant. Only one had evidence of acromegaly; there was no evidenceofthyroid deficiency, and onlyin case 2 (with radiological evidence of a pituitary tumour) and case 18 was there evidence of adrenocortical deficiency.
Galactorrhoea.-In the women the galactorrhoea had been present for eight months to 10 years before presentation but in two it was found only on examination; in two others it had started in the post-partum period (see table III ). Galactorrhoea in the men had been present for 3 to 15 months before presentation (see table IV) .
Gonadal Status.-Thirteen women had had amenorrhoea for between six months and six years, preceded in two cases by irregular periods. Periods were irregular without amenorrhoea in four patients. Two patients had evidence of the polycystic ovary syndrome on gynaecography, and one was hirsute. Two amenorrhoeic women initially appeared to be suffering from premature menopause but this was confirmed by ovarian biopsy in only one, the ovary from the other patient containing normal but undeveloped ovarian follicles. The four men all had absent or reduced potency.
Oestrogen-Progestogen Therapy.-In four women galactorrhoea was preceded by treatment with an oestrogen-progestogen oral contraceptive preparation prescribed for irregular menstruation. In one patient the milk appeared during treatment and in the others it occurred afterwards.
Pituitary Fossa Radiography.-Seven patients (six women and one man) were shown to have abnormal fossae, and in two of the men the appearance was equivocal in view of a double contour to the floor of the fossa.
Methods
Details of the methods for measuring serum immunoreactive prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and growth hormone (GH) have been given elsewhere (McNeilly, 1973; Mortimer et al., 1973; McNeilly and Hagan, 1974) . Plasma corticosteroids (Mattingly, 1962) and total urinary oestrogen (Brown et al., 1968, Searle) were measured fluorometrically. Plasma 17 p-hydroxyandrogens (17-OHA) as a measure of testosterone and dihydrotestosterone concentrations were assayed by the technique of Anderson (1970) .
In the assays used the normal ranges for serum LH (M.R.C. standard 68/40, 77 IU/ampoule) in male subjects was 0-8-13-3 U/1. and in female subjects in the follicular phase 1 4-9-8 U/1.; for FSH (M.R.C. standard 69/104, 10 IU/ampoule) the normal range in male subjects was 0-1-3-5 U/1. and in female subjects in the follicular phase 0-8-3-2 U/1. Plasma 17-OHA levels in male subjects normally range from 4 9 to 21-0 ng/ml.
Clomiphene Stimulation Test.-A dose of 3 mg/kg/day up to a maximum of 200 mg/day was given and the changes in serum gonadotrophin were followed for up to 10 days. In normal male subjects serum LH has been shown usuallyto riseabove the normal range in this time (Anderson et al., 1972 Gonadotrophin-releasing hormone tests were performed using 100 Fg gonadotrophin-releasing hormone (LH/FSH-RH, Hoechst) intravenously as a bolus with measurement of serum LH and FSH at 0, 20, and 60 minutes (Besser et al., 1972 b; Mortimer et al., 1973) .
Bromocriptine Therapy.-Treatment was usually started with a dose of 2-5 mg twice daily with food and increased after two months if full clinical improvement, as indicated by cessation of galactorrhoea and return of normal gonadal function, had not been attained. Treatment was arbitrarily stopped after 2 to 28 months in nine patients.
Results
The clinical and biochemical responses to treatment are shown in tables III and IV. Galactorrhoea was improved in all the patients. The improvement usually became noticeable within one week and ceased completely in 12 cases between one week and three months after starting therapy (tables III and IV). In five cases a trace of breast milk could still be expressed but the breasts did not discharge spontaneously and did not inconvenience the patient. In one patient with premature ovarian failure (case 13) the galactorrhoea was initially reduced but was still troublesome and could not be further influenced with oestrogen. In six of the patients inwhom treatment was withdrawn after one year or more the galactorrhoea recurred within three days to two weeks but responded again on resumption of bromocriptine. Two other patients had treatment stopped when they became pregnant.
Gonadal Status.-In 11 of the 13 patients with amenorrhoea (table III) menstruation was restored from 3 to 24 weeks after starting therapy with bromocriptine. The three patients whose gonadal function did not change had the following associated conditions: hypophysectomy and pituitary irradiation, acromegaly, andprematureovarian failure. Three patients previouslyhad irregular or heavy periods but not amenorrhoea with the galactorrhoea uncomplicated bypituitary disease, and these were restored to normal. Two patients attempted to become pregnant and both succeeded within two months; one was delivered of a normal child and the other was still pregnant. All four male patients (table IV) regained normal potency within six months. Therapy was withdrawn from nine responsive patients with the following results (tables III and IV): amenorrhoea recurred in four patients, periods became irregular in one, one was pregnant, and one man became impotent again.
Prolactin levels were measured basally in 17 patients and were raised in 12 (tables I and II). In response to bromocriptine serum prolactin was reduced to normal in each of the 11 patients in whom it was measured during treatment. In three patients prolactin levels were measured again after stopping treatment and they were again raised (tables III and IV).
Gonadotrophins.-Serum LH and FSH levels were detectable and normal in all patients before treatment except for cases 9, 13, and 15, in which they were raised ( Side Effects.-The only side effects were dyspepsia and nausea in five patients, and these occurrred about two hous after drug administration. The symptoms were particularly severe when treatment was initiated and when taken on an empty stomach; they could be avoided in most cases by taking the capsules in the middle of a meal. When symptoms continued the dose was reduced to 1 mg twice daily for a time, after which it could be gradually increased without recurrence of symptoms. In no case was it necessary to withhold treatment because of side effects. Though bromocriptine is an ergot alkaloid there were no symptoms or signs of ergotism or digital vasospasm. Five patients lost from 3-5 to 18 kg in weight over 3 to 18 months in spite of no apparent change in appetite or food intake. They had all gained this weight during the time that they had been galactorrhoeic.
Discussion
Altogether 20 of the 21 patients with galactorrhoea responded 421 to bromocriptine with reduction or cessation of galactorrhoea, and gonadal function was restored to normal in 14 of the 17 women and in all four men. When serum prolactin levels were measured during treatment they had in all cases been reduced to normal. When treatment was withdrawn galactorrhoea returned in all but one case and each patient again became hypogonadal but the symptoms abated again when bromocriptine therapy was resumed. Side effects were not a serious problem and were present in only a quarter of the patients, and only as therapy started. The early side effects of dyspepsia and nausea were avoided either by taking the drug with food or by reducing the dose for a short while; it was never necessary to withhold treatment because of side effects. These results confirm our preliminary findings and indicate that this compound may be used for continuous therapy without any escape of prolactin secretion or recurrence of galactorrhoea while on bromocriptine; prolonged treatment, up to 28 months in two cases, was devoid of adverse effects. We have no evidence, however, that the underlying pathological process is altered by bromocriptine therapy. Bromocriptine is a potent suppressor of prolactin secretion, and this has been confirmed both clinically and by measuring the circulating prolactin levels. Levodopa also suppresses prolactin secretion but has the disadvantage that its duration of action is short (Malarkey et al., 1971) , the incidence of side effects is high with doses necessary for adequate suppression, and it does not consistently improve galactorrhoea (Copinschi et al., 1973) . Recent work indicates that bromocriptine is a dopaminergic agonist (Corrodi et al., 1973) , and it is possible that its suppression of prolactin is through this mechanism but with a more prolonged length of action than levodopa. The therapeutic actions as well as the side effects would be compatible with this as they are very similar to those of levodopa.
Before treatment all the patients had either menstrual irregularities or amenorrhoea or impotence. Nevertheless, basal gonadotrophin levels were normal in all patients but two, both of whom had high rather than low levels. Excessive responses to LH/FSH-RH were seen in seven out of 13 patients tested but there was no correlation between gonadotrophin levels and the levels of circulating immunoreactive prolactin, and this excessive response to LH/FSH-RH confirms our previous report (Mortimer et al., 1973) . A normal response may also occur but we have not seen an impaired response in this context, in contrast to the experience of others (Zarate et al., 1973) .
In the galactorrhoea syndromes the gonadal function is usually impaired irrespective of whether immunoreactive prolactin levels are raised. When these patients are treated with bromocriptine and prolactin levels fall the gonadal function usually returns to normal. The only patients in whom this did not occur in the present series were two with pituitary tumour and one with a premature menopause. In five patients the gonadal function became normal with cessation of galactorrhoea even though radiographical evidence of a pituitary tumour was present. The hypogonadism which exists in association with the pretreatment galactorrhoea does not appear to be due to inadequate gonadotrophin synthesis or reserve as the responses to LH/FSH-RH are not impaired; however, the responses to clomiphene, which normally acts through the hypothalamus, are impaired. This situation is analogous to that in post-partum women in whom gonadotrophin secretion occurs early during lactation but does not cycle normally for some time and oestrogen secretion is low (Reyes et al., 1972) . During puerperal lactation the ovaries appear to be refractory to exogenous gonadotrophin during the time that prolactin secretion is increased (Zarate et al., 1972 ). It appears, therefore, that the raised prolactin levels in some way have antigonadotrophic actions at the gonadal level.
It seems likely that the hypogonadism in patients with pathological lactation is secondary to an inappropriately raised prolactin level, since the hypogonadism as well as the galactorrhoea respond to bromocriptine, which specifically blocks prolactin secretion. The reduction in prolactin appears to allow the circulating gonadotrophin levels to act on the gonad to stimulate steroidogenesis. The sex steroids then may feed back on the hypothalamus and pituitary to allow normal release of gonadotrophins, leading to a return of normal gonadal function, ovulation, and spermatogenesis.
One of the patients with persistently raised gonadotrophin levels, galactorrhoea, and amenorrhoea was of particular interest.
It was initially tempting to ascribe a diagnosis of a premature menopause to her; however, ovarian biopsy showed the presence of follicles and treatment with bromocriptine resulted in cessation of the galactorrhoea with regular menstruation. Similarly two patients had galactorrhoea with the polycystic ovary syndrome and both responded well. This association was described by Forbes et al. (1954) , and a number of their patients had hirsuties and seborrhoea as well as galactorrhoea and amenorrhoea or irregular periods. They also noted urinary 17-oxosteroid excretion at the upper limit of normal, or above, and we recorded this in six of our women and one of the men. It seems possible that prolactin may alter adrenocortical androgen production. The amenorrhoea associated with oral contraceptive medication also responds well to bromocriptine if galactorrhoea is present as well. A trial of this drug in post-oral contraceptive amenorrhoea without galactorrhoea is currently taking place.
Bromocriptine is an effective, safe, and satisfactory long-term treatment for galactorrhoea and it reverses the associated hypogonadism in both men and women. It appears to be the treatment of choice for this condition, since it is effective and devoid of adverse effects.
